

# Comparative Analysis of Prostate Cancer Gene Regulatory Networks via Hub Type Variation

Pegah Khosravi<sup>1,2</sup>, Vahid H. Gazestani<sup>3</sup>, Mohammad Akbarzadeh<sup>1</sup>, Samira Mirkhalaf<sup>1</sup>, Mehdi Sadeghi<sup>2,4</sup>, and Bahram Goliaei<sup>1\*</sup>

1. Department of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran

2. School of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran

3. Institute of Parasitology, McGill University, Montreal, Quebec, Canada

4. National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

## Abstract

**Background:** Prostate cancer is one of the most widespread cancers in men and is fundamentally a genetic disease. Identifying regulators in cancer using novel systems biology approaches will potentially lead to new insight into this disease. It was sought to address this by inferring gene regulatory networks (GRNs). Moreover, dynamical analysis of GRNs can explain how regulators change among different conditions, such as cancer subtypes.

**Methods:** In our approach, independent gene regulatory networks from each prostate state were reconstructed using one of the current state-of-art reverse engineering approaches. Next, crucial genes involved in this cancer were highlighted by analyzing each network individually and also in comparison with each other.

**Results:** In this paper, a novel network-based approach was introduced to find critical transcription factors involved in prostate cancer. The results led to detection of 38 essential transcription factors based on hub type variation. Additionally, experimental evidence was found for 29 of them as well as 9 new transcription factors.

**Conclusion:** The results showed that dynamical analysis of biological networks may provide useful information to gain better understanding of the cell.

## \* Corresponding author:

Bahram Goliaei, Ph.D.,  
Department of Bioinformatics,  
Institute of Biochemistry and  
Biophysics (IBB), University of  
Tehran, Tehran, Iran

Tel: +98 21 66498672

Fax: +98 21 66956985

## E-mail:

bahram.goliaei@gmail.com

Received: 7 May 2014

Accepted: 5 Jul 2014

*Avicenna J Med Biotech* 2015; 7(1): 8-15

**Keywords:** Gene regulatory networks, Prostate cancer, Transcription factors

## Introduction

The complexity and multigenic nature of cancer has necessitated various genome-wide studies to achieve a systems-level understanding of the key genetic mediators involved in prostate cancer<sup>1</sup>. Most diseases are due to the collapse of cellular processes together with interaction networks<sup>2</sup>. Therefore, exploring the biological network for complex diseases provides an understanding of the functional alterations in chronic diseases<sup>3</sup>.

Network-based approaches contain many clinical applications to explore human diseases systematically. A better understanding of the effects of cellular networks on disease progression may lead to the identification of disease genes which, in turn, may offer better targets for drug development<sup>4</sup>. One focal point in cancer analysis is the reconstruction of Gene Regulatory Networks (GRN)<sup>5</sup>. However, cancer progression is a dynamic process with multiple stages; so, reconstruction of one static GRN may not be informative enough for the inference. Instead, reconstructing stage-specific GRNs during cancer progression and then comparing

these GRNs would be beneficial to characterize the main genes and interactions involved in cancer progression.

The availability of genome-wide gene expression data has helped develop various state-of-art GRN reconstruction methods<sup>5-7</sup>. These methods seek to identify putative gene regulatory interactions by assuming that alterations in the expression level of a regulator (such as a transcription factor) have a direct effect on the cognate regulated genes.

Empirical evidence of extensive GRN rewiring during cancer progression, along with the availability of GRN reverse engineering approaches, have inspired us to conduct a systematic investigation to characterize the topological changes that occur in a prostate cell's GRN during cancer progression. Therefore, in this study, an attempt was made to reveal candidate disease-associated genes and biomarkers for prostate cancer progression by integrative gene expression profiling and network analysis at a systematic level. In this way, four stage-specific GRNs were reconstructed

based on a comprehensive prostate cancer gene expression dataset containing 171 different samples monitoring gene expression at different disease phases. Topological comparison of these four GRNs based on hub type variations recapitulates the previous findings about extensive GRN rewiring<sup>8</sup>. Through sub-network analysis, it is possible to identify significant genes which were supposed to change their hub type with highly relevant to specific phases of prostate cancer.

Enormous efforts have been made to identify biomarkers for various cancers by the analysis of different transcriptome data<sup>9-11</sup>. Moreover, there were similar studies for analysis of sub-networks or hub genes which had been helpful for the understanding of the metastasis of cancer at the molecular level<sup>12</sup>. Nonetheless, there are still few studies on identification of prostate cancer biomarkers for disease progression<sup>13</sup>. Therefore, in this study, a new integrative network-based approach was developed to detect party hubs and date hubs based on Degree and BN algorithms during cancer progression.

Our analysis led to identification of 38 important genes putatively involved in prostate cancer. Through extensive literature search, experimental evidences revealed the role of 76.3% of candidate genes in prostate cancer (Table 1). This level of experimental confirmation reflects the high accuracy of the proposed approach.

Our study hereby demonstrates a useful approach for analysis of prostate cancer at the systematic level. For the genome-wide investigations, this will be a fundamental attempt for future development of the translational medical informatics, which lead to better patient diagnostics with high-throughput data through systems biology<sup>14</sup>.

## Materials and Methods

### Network reverse engineering approaches

Reverse engineering of GRNs from whole genome data entails deciphering the underlying gene regulatory circuits by observing changes in gene expression profiles<sup>5</sup>. With advances in high-throughput technologies, several computational reverse engineering approaches using different statistical measures have been developed<sup>15-18</sup>, including information-theoretic network inference methods, which identify connections between genes by approximating the quantity of information common to any pair of genes. In the Dialogue on Reverse Engineering Assessment and Methods 5 (DREAM5) challenge, the context likelihood relevance (CLR) algorithm by Faith *et al*<sup>6</sup> had the best performance among information theory based approaches<sup>19</sup>.

Briefly, CLR determines an interaction between two genes to be significant by estimating the significance of their Mutual Information (MI) value against a background distribution of the MI values of every other pair involving one of the two genes of interest. In this way, the significance level is dynamically determined for

each interacting pair according to their expression profiles. Given a gene expression dataset and the significance scores calculated by CLR algorithm, the corresponding empirical False Discovery Rate (FDR) can be estimated by running the algorithm on randomly shuffled datasets. In this study, all GRNs were reconstructed using CLR with an FDR threshold of 0.05. It is important to note that CLR relies solely on the dependency between expression profiles to detect interactions. Consequently, the resulting network is a co-expression network; so, the GRN is extracted from this network by considering only interactions where at least one transcription factor is involved.

### Prostate cancer microarray data

Prostate cancer microarray data were downloaded from the Gene Expression Omnibus (GEO) database, accession number GSE6919<sup>20</sup>. This dataset contains 171 samples, including samples from normal prostate tissue free of any pathology (Normal with 18 samples), normal prostate tissue adjacent to tumors (Adjacent with 63 samples), primary prostate tumor tissue (Tumor with 65 samples), and metastatic prostate cancer (Metastasis with 25 samples). Microarray data were preprocessed and analyzed using the LIMMA package in R<sup>21</sup> which was originally developed for differential expression analysis of microarray data. Quantile normalization and a moderated t-statistic were used to find differentially expressed genes. More detailed descriptions of the methods can be found in the original publications.

### Network topological analysis

To predict the key regulators in the prostate cancer based on hub type variations, the stage-specific GRNs of prostate cancer were searched for transcription factors which either had a high number of connections or were bottleneck<sup>22,23</sup>. The bottleneck genes are important because if they are removed from a network, the network will be disrupted, as they are major intersections between clusters in the network<sup>24</sup>. To find such genes, all constructed GRNs were topologically analyzed following the same rules using cyto-Hubba package<sup>25</sup> which is a plugin for one of the most useful structural analysis software, Cytoscape<sup>26</sup>. Cyto-Hubba is used to detect the critical nodes of biological networks with many topological algorithms such as Degree, Bottleneck (BN), Maximum Neighborhood Component (MNC), Density of Maximum Neighborhood Component (DMNC), and a Double Screening Scheme (DSS)<sup>25-27</sup>. As mentioned before, Degree and BN were used to find the top ranked genes in all GRNs based on hub type variation which was the ultimate goal in this research.

## Results

### Stage specific network reconstruction of prostate cancer

Using the CLR algorithm, four independent networks related to the four different cell stages were reconstructed (Normal, Adjacent, Tumor, and Metasta-

Table 1. The function of 29 critical transcription factors putatively involved in prostate cancer

| Gene name     | Function                                                                                                                                                                        |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AR            | Androgen receptor gene transcripts are over-expressed in most metastatic prostate cancers (40).                                                                                 |
| ATF6          | ATF6-mediated apoptosis is reported in many cancers such as prostate cancer (49, 50).                                                                                           |
| SMAD3         | SMAD3 is an essential mediator of tumor suppression and apoptosis in prostate cancer (41).                                                                                      |
| GATA3         | Prostatic GATA3 is involved in androgen regulation of the prostate-specific antigen gene (51).                                                                                  |
| HLF           | HLF is involved in prostate cancer promotion and progression (52).                                                                                                              |
| PBX1          | The Pbx1-HoxC8 heterocomplex causes androgen-independent growth in prostate cancer (53).                                                                                        |
| FOXF1         | FOXF1 has high expression in normal prostate and its expression decreases in prostate cancer (39).                                                                              |
| TCF21         | TCF21 methylation levels accurately discriminate bladder and prostate cancerous tissues from their normal counterparts (54).                                                    |
| STAT1         | Progressive dysregulation of STAT1 in prostate cancer cells contributes to prostate tumor growth (55).                                                                          |
| EGR3          | EGR3 is significantly over-expressed in prostate cancer and is a candidate prognostic marker of poor outcome prostate cancer (56).                                              |
| FOS           | In human prostate cancer, up-regulation of FOS protein occurs in advanced diseases and correlates with MAPK pathway activation (57).                                            |
| KLF6          | KLF6 controls cell cycle progression and apoptosis and is usually inactivate in many cancers such as prostate, ovary and colon (37, 38).                                        |
| FOXA1         | High-level FOXA1 expression is associated with the development of metastatic prostate cancer and could be used to classify patients who are at higher risk for metastases (58). |
| ELK4          | ELK4 plays important roles in cell growth regulation of prostate cancer cells. The level of the transcript correlates with the progression of the disease (59).                 |
| HOXC6         | Down-regulation of HOXC6 due to decreased proliferation rates of cell line and the over-expression of it rescues the cells from apoptosis in prostate cancer (60).              |
| VDR           | Studies discriminated the impact of VDR ligands upon prostate cancer cell proliferation, differentiation, and apoptosis (42).                                                   |
| RARB          | RARB gene methylation in prostate samples is associated with an increased risk of subsequent prostate cancer (61).                                                              |
| EZH2          | Over-expression of EZH2 causes invasion and growth of prostate cells. It is also a good biomarker for detection of the problem at an advanced stage (62).                       |
| TFAP2A (AP-2) | Cytoplasmic expression of AP-2 is reduced in prostate cancer cells (63).                                                                                                        |
| JUNB          | JUNB has an important role in controlling prostate cancer and can be a target for cancer therapy (64).                                                                          |
| SNAI2         | Down-regulation of SNAI2 is associated with primary prostate cancers and is a negative regulator of proliferation in the cancer cells (65).                                     |
| ZEB1          | Cancerous phenotype in prostate cancer cells is associated with increased expression of ZEB1 (66).                                                                              |
| MXD4 (MAD4)   | MXD4 which is known to have antitumor properties is significantly up-regulated in treated PC (67).                                                                              |
| MAZ           | MAZ expression deregulation relates to progression of many cancer types and plays an important role in PCa pathogenesis (68).                                                   |
| HOXB13        | Recurrent mutation in HOXB13 associates with an increased risk of hereditary prostate cancer (69).                                                                              |
| SIM2          | Studies suggested an involvement of SIM2 in prostate tumor cell and cancer progression (70).                                                                                    |
| INSM1         | Investigation showed that INSM1 remarkably up-regulates at the advanced PC stages (71).                                                                                         |
| PLAGL1        | PLAGL1 is a tumor suppressor gene that inhibits growth of tumor cells by controlling apoptosis and cell-cycle progression in prostate cancer (72).                              |
| FOXC1         | It was indicated that FOXC1 links to androgen-associated growth status of prostate cancer (39).                                                                                 |

sis). The metastasis GRN had the lowest number of interactions with 2505 interactions while the other three GRNs had around 3000 interactions each. Additionally, topological analysis of the GRNs revealed that all four networks exhibited the small-world property<sup>28</sup> and scales-free architecture<sup>29</sup> which are the well-known characteristics of most biological networks (Figure 1). All four reconstructed GRNs were mainly composed of the same set of genes; however, the conserved interactions among these four networks were very low and the metastasis network had the most unique interactions (Figure 2).

#### **Detection of essential transcription factors involved in the prostate cancer**

Considering the importance of hub and bottleneck proteins in the structure of GRNs, the 50 highest-ranked genes were identified for each stage-specific GRN based on their degree and bottleneck scores, separately. Top 50 genes were selected based on previous studies that showed the highest percentage of critical proteins found in top 50 ones based on Degree and BN

algorithm<sup>25</sup>. Although there were four conditions that resulted in detection of 200 genes, 144 of 200 genes had overlap during various conditions. Consequently, 56 unique candidate genes were selected for further analysis.

In each GRN, these 56 genes were categorized based on their degree and bottleneck scores in four groups: 1) Hub-NonBottleneck: genes with high degrees and low bottleneck scores are putative party hubs<sup>30</sup>; 2) Hub-Bottleneck: genes with high degrees and high bottleneck scores are putative date hubs<sup>30</sup>; 3) NonHub-Bottleneck: genes with low degrees and high bottleneck scores; 4) NonHub-NonBottleneck: genes with low degrees and low bottleneck scores.

The results showed hub type variation for 38 genes across different stages, whereas 18 other genes were functionally conserved as date hubs under all conditions (Table 2).

Sub-networks consisting of the first neighborhoods of the 38 critical bottleneck transcription factors were extracted and compared, revealing changes in the




Figure 1. The architecture of gene regulatory networks. All four networks (normal, adjacent, tumor and metastasis networks) follow the well-known characteristics of most biological networks; A) scale-free architecture defined as few highly connected genes (hubs) that link the other less connected genes to the network; B) small-world property which means any two genes in the network can be connected by relatively short paths through all interactions.

number of interactions and gene targets between the stages. For some transcription factors such as STAT1, AR, HLF, ZEB1, TCF21, ISL1, KLF6, HOXB13, SIM2 and FOXA1, the number of interactions in the metastasis stage decreased dramatically (Table 3); the interaction numbers of other transcription factors, such as ZNF-529, FOXC1, MNX1, and JUNB, increased considerably in the metastasis stage, indicating network rewiring (Table 3). These 14 transcription factors (Fig-

ure 2) showed dramatic changes in their number of interactions (fold change  $\geq 2$ ) during the cancer progression (Table 3).

### Discussion

To reconstruct cell stage specific GRNs, an attempt was made to focus on the available comprehensive transcriptome dataset, originally published in <sup>20</sup>. This dataset was generated by sampling from four different

Table 2. 56 transcription factors showed different topological characteristics in different stages

| Gene name | N  | A  | T  | M  | Gene Name | N  | A  | T  | M  |
|-----------|----|----|----|----|-----------|----|----|----|----|
| HOXB13    | PH | DH | PH | DH | ZNF516    | DH | DH | DH | DH |
| ZEB1      | PH | DH | DH | DH | GATA3     | DH | DH | DH | NB |
| SIM2      | PH | DH | DH | NB | ZNF423    | DH | DH | DH | DH |
| TFAP2A    | PH | DH | DH | DH | KLF6      | DH | NN | NN | DH |
| ZNF205    | PH | DH | DH | DH | ZNF91     | DH | DH | DH | DH |
| EZH2      | PH | NN | DH | PH | ETS2      | DH | DH | DH | DH |
| MXD4      | PH | DH | DH | DH | NFYA      | DH | DH | DH | DH |
| ZNF146    | PH | DH | DH | DH | MEIS1     | DH | DH | DH | DH |
| CAMTA1    | PH | NB | NN | DH | SMAD3     | DH | NB | DH | DH |
| MAZ       | PH | DH | DH | DH | MEIS2     | DH | DH | DH | DH |
| PLAGL1    | PH | DH | DH | PH | STAT5A    | DH | DH | DH | DH |
| HOXC6     | DH | PH | DH | PH | PRRX1     | DH | DH | DH | DH |
| FOS       | DH | PH | DH | DH | NHLH2     | DH | NN | DH | DH |
| ELK4      | DH | PH | NN | DH | FOXN3     | DH | DH | DH | DH |
| NKX2-2    | DH | DH | PH | DH | EGR3      | DH | DH | DH | NN |
| MNX1      | NB | NN | PH | DH | ID1       | DH | DH | DH | DH |
| AR        | DH | DH | DH | PH | NR4A1     | DH | DH | DH | DH |
| PBX1      | DH | DH | DH | PH | NR1H2     | DH | DH | DH | DH |
| FOXA1     | DH | DH | DH | PH | FOXF1     | DH | DH | DH | NN |
| INSM1     | NB | DH | NN | PH | ATF6      | DH | DH | NB | DH |
| MEF2C     | DH | DH | DH | DH | STAT6     | DH | DH | DH | DH |
| STAT1     | DH | DH | DH | NB | VDR       | DH | DH | NN | DH |
| NR3C1     | DH | DH | DH | DH | FOXC1     | NB | DH | DH | DH |
| HLF       | DH | DH | DH | NB | STAT2     | NB | DH | NB | DH |
| TP63      | DH | DH | DH | DH | JUNB      | NN | DH | DH | DH |
| TCF21     | DH | DH | DH | NB | RARB      | NB | DH | DH | NB |
| ISL1      | DH | NB | DH | NB | SNAI2     | NB | NN | DH | NB |
| EGR1      | DH | DH | DH | DH | ZNF529    | NN | NN | NB | DH |

N) Normal; A) Adjacent; T) Tumor; M) Metastasis; DH) Date Hub; PH) Party Hub; NB) Nonhub-Bottleneck; NN) Nonhub-Nonbottleneck.




Figure 2. Number of interactions. This figure shows the GRNs for 14 TFs (orange nodes) that change their interaction numbers dramatically during cancer progression; A) Normal stage; B) Adjacent stage; C) Tumor stage; D) Metastasis stage which reflects the high level of rewiring of gene regulatory interactions.

types of prostate tissues including normal cells (Normal), normal cells adjacent to cancer cells (Adjacent), primary tumor cells (Tumor), and metastatic cells (Me-

tastasis). In our approach, genes were analyzed and prioritized based on the transcriptome data. Hence, it was possible to make reliable predictions only for genes with altered expression level across various conditions. To focus on these genes, only up/down-regulated genes were considered (fold change  $\geq 2$  and  $p < 0.05$ ) in at least one cell stage (978 genes). Also, enrichment of known cancer genes was checked among this set by using a previously curated list of 555 high confidence cancer genes, originally published in <sup>31</sup>. 100 genes were collected and identified as mediators in metastatic prostate cancer from <sup>32</sup>, and 276 genes were added and annotated as either a cancer pathway or prostate cancer gene in the KEGG database. It was found that the cancer-related genes were about 1.55-fold (hypergeometric two-tailed test,  $p = 2.52E-6$ ) and the prostate cancer-related genes were about 2.22-fold enriched (hypergeometric two-tailed test,  $p = 6.07E-6$ ) in our selected gene set which were fluctuated during prostate cancer.

To identify master regulators and their associated circuits governing cell-specific behavior in each state, the GRNs of prostate cells were compared in different stages with each other. Because the CLR algorithm merely relies on the similarity of expression patterns to

Table 3. The number of interactions for 14 out of 38 transcription factors changed dramatically from normal to metastasis stage (fold change &gt;2)

| Gene name | Normal | Adjacent | Tumor | Metastasis | Fold change |
|-----------|--------|----------|-------|------------|-------------|
| HOXB13    | 143    | 176      | 43    | 52         | 2.75        |
| ZEB1      | 135    | 137      | 74    | 33         | 4.09        |
| SIM2      | 120    | 132      | 115   | 25         | 4.80        |
| TFAP2A    | 60     | 30       | 25    | 63         | 0.95        |
| ZNF205    | 56     | 38       | 28    | 44         | 1.27        |
| EZH2      | 46     | 24       | 81    | 81         | 1.76        |
| MXD4      | 43     | 31       | 32    | 69         | 1.60        |
| ZNF146    | 42     | 45       | 60    | 72         | 1.71        |
| CAMTA1    | 41     | 22       | 21    | 37         | 1.11        |
| MAZ       | 39     | 64       | 56    | 46         | 0.85        |
| PLAGL1    | 26     | 36       | 39    | 30         | 0.87        |
| HOXC6     | 34     | 53       | 78    | 47         | 1.38        |
| FOS       | 63     | 49       | 69    | 65         | 0.97        |
| ELK4      | 35     | 34       | 17    | 33         | 0.94        |
| NKX2-2    | 28     | 33       | 43    | 30         | 0.93        |
| MNX1      | 26     | 20       | 29    | 70         | 2.69        |
| AR        | 103    | 61       | 35    | 48         | 2.15        |
| PBX1      | 45     | 64       | 117   | 37         | 0.82        |
| FOXA1     | 108    | 153      | 41    | 34         | 3.18        |
| INSM1     | 21     | 26       | 23    | 32         | 0.66        |
| STAT1     | 113    | 97       | 122   | 16         | 7.06        |
| HLF       | 123    | 120      | 86    | 25         | 4.92        |
| TCF21     | 59     | 102      | 58    | 25         | 2.36        |
| ISL1      | 65     | 26       | 68    | 22         | 2.95        |
| GATA3     | 42     | 34       | 68    | 22         | 1.91        |
| KLF6      | 76     | 26       | 20    | 37         | 2.05        |
| SMAD3     | 41     | 18       | 28    | 40         | 1.03        |
| NHLH2     | 27     | 18       | 32    | 34         | 0.79        |
| EGR3      | 32     | 35       | 40    | 26         | 1.23        |
| FOXF1     | 32     | 151      | 129   | 26         | 0.81        |
| ATF6      | 44     | 27       | 17    | 40         | 1.1         |
| VDR       | 30     | 27       | 18    | 33         | 0.91        |
| FOXC1     | 14     | 42       | 68    | 33         | 2.36        |
| STAT2     | 23     | 32       | 19    | 34         | 0.68        |
| JUNB      | 21     | 50       | 47    | 48         | 2.29        |
| RARB      | 21     | 31       | 27    | 26         | 0.81        |
| SNAI2     | 25     | 25       | 34    | 24         | 1.04        |
| ZNF529    | 10     | 26       | 24    | 42         | 4.2         |

infer interactions, constructed networks in this step contain both regulatory interactions (interactions between regulated genes and their putative regulators) as well as interactions between co-regulated genes (non-regulatory interactions). Hereafter, these networks are called co-expression networks. To extract gene regulatory interactions from these networks, only interactions involved at least one human transcription factor were considered and a list of them were extracted from<sup>33,34</sup>. These networks are referred to as GRNs.

To predict the key genes in the prostate cancer, an attempt was made to find the stage-specific co-expression networks of prostate cancer for high connectivity

(hub) or bottleneck genes<sup>22,23</sup>. Hub and bottleneck properties are considered important centrality indices because they are major intersections between clusters in the network and if they are removed from a network, the network will be disrupted<sup>24</sup>. Han *et al* suggested the existence of two types of protein hubs in the protein-protein interaction networks, namely party hubs and date hubs<sup>30</sup>. Although both interact with many proteins, the difference is that party hubs are proteins that interact with many other proteins simultaneously, whereas date hubs interact with their partners asynchronously<sup>30</sup>. By definition, the bottleneck proteins are responsible for the interconnection of clusters in the network, and thus bottlenecks with high degrees are most likely to be date hubs which contain groups of genes that assist in presenting common functions<sup>24,35</sup>. The obtained results recapitulate previous findings in which some active sub-networks contained regulatory interactions were supplanted by new interactions which changed their degrees during different conditions<sup>36</sup>.

The result also reflected the high level of rewiring of gene regulatory circuits during cancer progression, as suggested elsewhere<sup>8</sup>. As shown in table 3, for example, more than 2-fold decrease in the number of interactions for KLF6 was observed which controlled cell cycle progression and apoptosis. Indeed, experimental data suggest that KLF6 is inactivated in many cancers such as prostate, ovary and colon<sup>37,38</sup>. On the other hand, consistent with more than 2-fold increase in the number of interactions (from 14 in normal stage to 33 in the metastasis stage) for FOXC1 (Table 3), it was indicated that this gene is linked to androgen dependent growth of prostate cancer<sup>39</sup>.

Our result led to identification of 38 transcription factors which were bottleneck and changed their interaction during cancer progression. Although the functional role of some famous transcription factors such as AR, SMAD3 and VDR are well known as genes linked to prostate cancer<sup>40-42</sup>, the 9 transcription factors (CAMTA1, ISL1, MNX1, NHLH2, NKX2-2, STAT2, ZNF146, ZNF205, and ZNF529) are new candidates that may have critical roles in prostate cancer based on topological significance and regulatory changes during cancer progression. Among the remaining 9 transcription factors, 5 of them were associated with other cancer types. ZNF146, CAMTA1, NKX2-2, MNX1, and ISL1 are most prominent in colorectal cancer, neuroblastoma, Ewing's sarcoma, leukemia and breast cancer, and bladder cancers, respectively<sup>43-48</sup>. No evidence could be found to show the relationship between the 4 remaining transcription factors and any type of cancer.

## Conclusion

In this paper, an accurate network-based framework for the analysis of transcriptome data was presented. The analysis of prostate state specific GRNs revealed 38 transcription factors which are critically important for prostate cancer progression. Also, 14 transcription

factors were identified to be linked putatively to prostate cancer metastasis stage, so they would be used as key factors for future research in the field of cancer studies. Additionally, experimental evidences revealed the role of 29 of candidate transcription factors in prostate cancer.

The low number of predictions and high degree of overlap with previously known events in the prostate cancer demonstrate the high efficiency of our approach. In addition, the low number of predicted gene sets makes it easy to design follow up experiments to validate the results. In this study, it is believed that the results may provide critical information to gain better understanding of networks dynamics in the cell through complex diseases such as cancer.

### Acknowledgement

Pegah Khosravi has been supported by the School of Biological Sciences of Institute for Research in Fundamental Sciences (IPM). Vahid H. Gazestani has been supported by CIHR Systems Biology Fellowship. The authors would like to thank Dr. Gary Bader and Dr. Juri Reimand in the Bader's lab for their invaluable insights.

### References

- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10(8):789-799.
- Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. *Proc Natl Acad Sci USA* 2007;104(21):8685-8690.
- Paik H, Heo HS, Ban HJ, Cho SB. Unraveling human protein interaction networks underlying co-occurrences of diseases and pathological conditions. *J Transl Med* 2014;12:99.
- Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. *Nat Rev Genet* 2011;12(1):56-68.
- Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. *BMC Bioinformatics* 2006; 7 Suppl 1:S7.
- Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G, et al. Large-scale mapping and validation of *Escherichia coli* transcriptional regulation from a compendium of expression profiles. *PLoS Biol* 2007;5(1):e8.
- Butte AJ, Kohane IS. Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements. *Pac Symp Biocomput* 2000:418-429.
- Huang S, Ingber DE. A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. *Breast Dis* 2006;26:27-54.
- Kallioniemi O. Functional genomics and transcriptomics of prostate cancer: promises and limitations. *BJU Int* 2005;96 Suppl 2:10-15.
- Jiang J, Cui W, Vongsangnak W, Hu G, Shen B. Post genome-wide association studies functional characterization of prostate cancer risk loci. *BMC Genomics* 2013;14 Suppl 8:S9.
- Tang Y, Yan W, Chen J, Luo C, Kaipia A, Shen B. Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. *BMC Syst Biol* 2013;7 Suppl 3:S6.
- Ideker T, Sharan R. Protein networks in disease. *Genome Res* 2008;18(4):644-652.
- Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol* 2009;27(2):199-204.
- Brahmachari SK. Introducing the medical bioinformatics in Journal of Translational Medicine. *J Transl Med* 2012; 10:202.
- Friedman N. Inferring cellular networks using probabilistic graphical models. *Science* 2004;303(5659):799-805.
- Schafer J, Strimmer K. An empirical Bayes approach to inferring large-scale gene association networks. *Bioinformatics* 2005;21(6):754-764.
- Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. *Proc Natl Acad Sci USA* 2000;97(22): 12182-12186.
- Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. *Nat Genet* 2005;37(4):382-390.
- Marbach D, Costello JC, Kuffner R, Vega NM, Prill RJ, Camacho DM, et al. Wisdom of crowds for robust gene network inference. *Nat Methods* 2012;9(8):796-804.
- Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. *BMC Cancer* 2007;7:64.
- Smyth GK. Limma: linear models for microarray data. In: Huber W, editor. *Bioinformatics and computational biology solutions using R and bioconductor*. New York: Springer; 2005. p. 397-420.
- Freeman LC. Set of measures of centrality based on betweenness. *Sociometry* 1977;40(1):35-41.
- Girvan M, Newman MEJ. Community structure in social and biological networks. *Proc Natl Acad Sci USA* 2002; 99(12):7821-7826.
- Yu HY, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: Correlation with gene essentiality and expression dynamics. *PLoS Comput Biol* 2007;3(4):713-720.
- Lin CY, Chin CH, Wu HH, Chen SH, Ho CW, Ko MT. Hubba: hub objects analyzer--a framework of interactome hubs identification for network biology. *Nucleic Acids Res* 2008;36(Web Server issue):W438-443.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;13(11):2498-2504.

27. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. *Nat Protoc* 2007; 2(10):2366-2382.
28. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. *Nature* 1998;393(6684):440-442.
29. Barabasi AL, Albert R. Emergence of scaling in random networks. *Science* 1999;286(5439):509-512.
30. Han JD, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV, et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature* 2004;430(6995):88-93.
31. Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. *Mol Syst Biol* 2013;9:637.
32. Ergun A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ. A network biology approach to prostate cancer. *Mol Syst Biol* 2007;3:82.
33. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. *Nat Rev Genet* 2009; 10(4):252-263.
34. Kummerfeld SK, Teichmann SA. DBD: a transcription factor prediction database. *Nucleic Acids Res* 2006;34: D74-D81.
35. Dunn R, Dudbridge F, Sanderson CM. The use of edge-betweenness clustering to investigate biological function in protein interaction networks. *BMC Bioinformatics* 2005;6:39.
36. Luscombe NM, Babu MM, Yu H, Snyder M, Teichmann SA, Gerstein M. Genomic analysis of regulatory network dynamics reveals large topological changes. *Nature* 2004; 431(7006):308-312.
37. Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, et al. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. *J Biol Chem* 2011;286(12):9968-9976.
38. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. *Science* 2001;294(5551):2563-2566.
39. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. *BJU Int* 2009;103(11):1574-1580.
40. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. *Nephrourol Mon* 2013;5(3):792-800.
41. Reed JA, Lin Q, Chen D, Mian IS, Medrano EE. SKI pathways inducing progression of human melanoma. *Cancer Metastasis Rev* 2005;24(2):265-272.
42. Skinner HG, Schwartz GG. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev* 2008;17(9):2302-2305.
43. Ferbus D, Bovin C, Validire P, Goubin G. The zinc finger protein OZF (ZNF146) is overexpressed in colorectal cancer. *J Pathol* 2003;200(2):177-182.
44. Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. *Clin Cancer Res* 2006;12(1):131-138.
45. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. *Cancer Cell* 2006;9(5):405-416.
46. Nagel S, Kaufmann M, Scherr M, Drexler HG, MacLeod RA. Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1). *Genes, Chromosomes Cancer* 2005;42(2):170-178.
47. Lian ZQ, Wang Q, Li WP, Zhang AQ, Wu L. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. *Int J Oncol* 2012;41(2):629-638.
48. Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD, Kim SK, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. *Int J Cancer* 2013;133(5):1135-1142.